SGHT: Rentang target analis Sight Sciences Inc.

Sight Sciences, Inc. (SGHT) develops automated micro-instrumentation for glaucoma treatment, streamlining the workflow for surgeons. The company generates revenue by supplying dry eye therapy systems and micro-invasive intervention tools to ophthalmology centers. Omni procedures provide a steady cash flow, with the indicator standing at 10.13. Price action on the GURU.Markets platform confirms the impact of these fundamental factors on the asset's market value.

This indicator represents the weighted average expected share value, which filters out market noise and determines the objective vector of the asset's fundamental value. By analyzing the overall target price consensus of investment firms, an investor can see the resilience of Sight Sciences, Inc., whose ophthalmic equipment production is shielded from geopolitical risks and trade restrictions, ensuring stable global distribution.